1072708-39-4 Usage
Molecular Weight
554.2 g/mol
Structure
Furo[2,3-b]pyridine core
1-one group
2,2-dimethylpropan-1-one side chain
4-bromo-2-chlorophenyl and 4-chlorophenyl substituents on the furo[2,3-b]pyridine core
Bromomethyl group on the furo[2,3-b]pyridine core
Functional Groups
Fused aromatic ring system (furo[2,3-b]pyridine)
Carbonyl group (1-one)
Alkyl side chain (2,2-dimethylpropan-1-one)
Halogen substituents (bromine and chlorine)
Halogen Substituents
Bromine (Br) on the phenyl rings
Chlorine (Cl) on the phenyl rings
Potential Applications
Pharmaceutical research
Chemical applications
Biological activity due to unique structure and halogen substituents
Safety Precautions
Appropriate handling and use due to complex structure and potential chemical reactivity
Use of protective equipment and following safety guidelines when working with this compound
Check Digit Verification of cas no
The CAS Registry Mumber 1072708-39-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,7,2,7,0 and 8 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1072708-39:
(9*1)+(8*0)+(7*7)+(6*2)+(5*7)+(4*0)+(3*8)+(2*3)+(1*9)=144
144 % 10 = 4
So 1072708-39-4 is a valid CAS Registry Number.
1072708-39-4Relevant articles and documents
Substituted furo[2,3-B] pyridine derivatives as cannabinoid-1 receptor modulators
-
Page/Page column 30, (2008/12/04)
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.